Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
On 27 July, a study was published analyzing cardiovascular adverse events following COVID-19 vaccination reported to the global VigiBase database.
For the cardiovascular system, 4,863 AEFI were reported for BNT162b2 Pfizer, AstraZeneca, Moderna, and other COVID-19 vaccines. Common adverse events observed with vaccines under study were tachycardia (16.41%), flushing (12.17%), hypertension (5.82%), hypotension (3.60%) and peripheral coldness (2.41%). Based on disproportionality analysis (IC025 values), acute myocardial infarction, cardiac arrest, and circulatory collapse were linked to the vaccines in the >75 years age group. Hypertension, severe hypertension, supraventricular tachycardia, sinus tachycardia, and palpitations were associated with all age groups and both sexes. In addition, abnormal ECG findings and increases in C-reactive protein, D-dimer, and troponin were reported.
It should be emphasized that this is a descriptive analysis, and that causality was not analyzed. Cardiovascular events of this type need to be monitored, and studies conducted to gain an understanding of causality.
Source: Jeet Kaur R, Dutta S, Charan J, Bhardwaj P, Tandon A, Yadav D, Islam S, Haque M. Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. Int J Gen Med. 2021;14:3909–3927. https://doi.org/10.2147/IJGM.S324349